Hunter Perkins Capital Management LLC Has $6.52 Million Stock Holdings in Johnson & Johnson $JNJ

Hunter Perkins Capital Management LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 41.2% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 31,489 shares of the company’s stock after selling 22,056 shares during the quarter. Johnson & Johnson comprises 1.5% of Hunter Perkins Capital Management LLC’s holdings, making the stock its 18th biggest position. Hunter Perkins Capital Management LLC’s holdings in Johnson & Johnson were worth $6,517,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. AustralianSuper Pty Ltd grew its position in Johnson & Johnson by 632.0% in the third quarter. AustralianSuper Pty Ltd now owns 89,183 shares of the company’s stock valued at $16,536,000 after acquiring an additional 77,000 shares during the last quarter. J.W. Cole Advisors Inc. boosted its stake in shares of Johnson & Johnson by 2.2% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company’s stock valued at $24,278,000 after purchasing an additional 2,769 shares in the last quarter. Guinness Asset Management LTD grew its holdings in shares of Johnson & Johnson by 0.4% during the 3rd quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company’s stock valued at $251,216,000 after purchasing an additional 5,994 shares during the last quarter. Treasurer of the State of North Carolina increased its position in Johnson & Johnson by 8.3% during the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock worth $188,638,000 after purchasing an additional 94,957 shares in the last quarter. Finally, National Pension Service boosted its position in Johnson & Johnson by 3.2% in the third quarter. National Pension Service now owns 4,926,569 shares of the company’s stock valued at $913,484,000 after buying an additional 151,707 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $242.22 on Tuesday. The firm has a market cap of $583.40 billion, a P/E ratio of 21.92, a P/E/G ratio of 2.37 and a beta of 0.34. The stock’s 50 day moving average is $237.87 and its 200 day moving average is $211.39. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. Johnson & Johnson has a one year low of $141.50 and a one year high of $251.71.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The firm had revenue of $24.28 billion during the quarter. As a group, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio is presently 47.06%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Royalty Pharma agreed to provide $500 million of R&D co‑funding for JNJ‑4804, a novel co‑antibody targeting IL‑23 and TNF; the deal de‑risks development costs, validates the program and accelerates immunology exposure for J&J. Royalty Pharma and J&J partner to develop autoimmune treatment Johnson & Johnson’s JNJ-4804 Deal Adds Weight To Immunology Story
• Positive Sentiment: J&J presented first randomized Phase 2 data for JNJ‑1900 (NBTXR3) in stage‑3 inoperable lung cancer at a major conference — early positive clinical readouts support the oncology pipeline and partner collaborations. NANOBIOTIX Announces Presentation of First Data
• Positive Sentiment: Johnson & Johnson MedTech shared favorable findings for the Impella CP device in left‑ventricular support at ACC, which may support near‑term MedTech revenue momentum and competitive positioning. Johnson & Johnson MedTech shares findings for Impella CP
• Positive Sentiment: Royal Bank of Canada reaffirmed an “outperform” rating and a $255 price target, providing analyst backing that supports upside expectations versus current levels. RBC reaffirmation / Benzinga
• Positive Sentiment: Multiple outlets highlighted J&J as a top dividend/defensive stock and noted an upcoming dividend increase window — this bolsters demand from income and defensive investors given J&J’s low beta and long dividend history. This is Why Johnson & Johnson is a Great Dividend Stock Dividend increases coverage
• Neutral Sentiment: Industry research forecasts growth in the non‑muscle invasive bladder cancer market and lists J&J among leading competitors — a positive long‑term market backdrop but not an immediate catalyst. Non‑Muscle Invasive Bladder Cancer Market report

Analysts Set New Price Targets

JNJ has been the topic of several recent research reports. Loop Capital set a $220.00 price objective on Johnson & Johnson in a report on Tuesday, January 27th. Wells Fargo & Company increased their target price on Johnson & Johnson from $230.00 to $240.00 and gave the company an “overweight” rating in a research report on Thursday, January 22nd. Barclays boosted their price target on Johnson & Johnson from $217.00 to $234.00 and gave the stock an “equal weight” rating in a report on Thursday, March 19th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, December 11th. Finally, Citigroup lifted their target price on shares of Johnson & Johnson from $250.00 to $274.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $236.91.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 22,623 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the sale, the executive vice president owned 26,769 shares of the company’s stock, valued at approximately $6,540,469.77. This represents a 45.80% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 30,142 shares of company stock worth $7,360,528 over the last 90 days. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.